Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2006, Article ID 67120, 6 pages
Research Communication

Role of Interleukin-18 in Modulation of Oral Carcinoma Cell Proliferation

Department of Microbiology, Faculty of Science, Prince of Songkla University, Hat Yai, Songkla 90112, Thailand

Received 22 January 2006; Accepted 24 February 2006

Copyright © 2006 Athip Nilkaeo and Suthinee Bhuvanath. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K Nakanishi, T Yoshimoto, H Tsutsui, and H Okamura, “Interleukin-18 regulates both Th1 and Th2 responses,” Annual Review of Immunology, vol. 19, pp. 423–474, 2001. View at Publisher · View at Google Scholar
  2. C A Dinarello, “Interleukin-18,” Methods, vol. 19, no. 1, pp. 121–132, 1999. View at Publisher · View at Google Scholar
  3. O Adachi, T Kawai, K Takeda et al., “Targeted disruption of the MyD88 gene results in loss of IL-1- and IL- 18-mediated function,” Immunity, vol. 9, no. 1, pp. 143–150, 1998. View at Publisher · View at Google Scholar
  4. J E Sims, “IL-1 and IL-18 receptors, and their extended family,” Current Opinion in Immunology, vol. 14, no. 1, pp. 117–122, 2002. View at Publisher · View at Google Scholar
  5. U Kalina, D Kauschat, N Koyama et al., “IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21,” Journal of Immunology, vol. 165, no. 3, pp. 1307–1313, 2000. View at Google Scholar
  6. S Akira, “The role of IL-18 in innate immunity,” Current Opinion in Immunology, vol. 12, no. 1, pp. 59–63, 2000. View at Publisher · View at Google Scholar
  7. T Yoshimoto, K Takeda, T Tanaka et al., “IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production,” Journal of Immunology, vol. 161, no. 7, pp. 3400–3407, 1998. View at Google Scholar
  8. G Cai, R A Kastelein, and C A Hunter, “IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18,” European Journal of Immunology, vol. 29, no. 9, pp. 2658–2665, 1999. View at Publisher · View at Google Scholar
  9. I B McInnes, J A Gracie, B P Leung, X Q Wei, and F Y Liew, “Interleukin 18: a pleiotropic participant in chronic inflammation,” Immunology Today, vol. 21, pp. 312–315, 2000. View at Publisher · View at Google Scholar
  10. E Esfandiari, I B McInnes, G Lindop et al., “A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease,” Journal of Immunology, vol. 167, no. 9, pp. 5338–5347, 2001. View at Google Scholar
  11. V S Tokmadzic, Y Tsuji, T Bogovic et al., “IL-18 is present at the maternal-fetal interface and enhances cytotoxic activity of decidual lymphocytes,” American Journal of Reproductive Immunology, vol. 48, no. 4, pp. 191–200, 2002. View at Publisher · View at Google Scholar
  12. J Golab, “Interleukin 18-interferon gamma inducing factor-a novel player in tumour immunotherapy?” Cytokine, vol. 12, no. 4, pp. 332–338, 2000. View at Publisher · View at Google Scholar
  13. A Agarwal, M Rani, G K Saha et al., “Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma,” Immunological Investigations, vol. 32, no. 1-2, pp. 17–30, 2003. View at Publisher · View at Google Scholar
  14. M B Moore, Z B Kurago, C A Fullenkamp, and C T Lutz, “Squamous cell carcinoma cells differentially stimulate NK cell effector functions: the role of IL-18,” Cancer Immunology, Immunotherapy, vol. 52, no. 2, pp. 107–115, 2003. View at Google Scholar
  15. M Okamoto, G Ohe, S Furuichi et al., “Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells,” Anticancer Research, vol. 22, no. 6 A, pp. 3229–3239, 2002. View at Google Scholar
  16. E Jablonska, W Puzewska, Z Grabowska, J Jablonski, and L Talarek, “VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer,” Cytokine, vol. 30, no. 3, pp. 93–99, 2005. View at Publisher · View at Google Scholar
  17. P Chomczynski and N Sacchi, “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction,” Analytical Biochemistry, vol. 162, no. 1, pp. 156–159, 1987. View at Publisher · View at Google Scholar
  18. A Carbone, U Rodeck, F A Mauri et al., “Human pancreatic carcinoma cells secrete bioactive Interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response,” Cancer Biology and Therapy, vol. 4, no. 2, pp. 231–241, 2005. View at Google Scholar
  19. J Wang, Y Kobayashi, A Sato, E Kobayashi, and T Murakami, “Synergistic anti-tumor effect by combinatorial gene-gun therapy using IL-23 and IL-18 cDNA,” Journal of Dermatological Science, vol. 36, no. 1, pp. 66–68, 2004. View at Publisher · View at Google Scholar
  20. P Hegardt, B Widegren, L Li et al., “Nitric oxide synthase inhibitor and IL-18 enhance the anti-tumor immune response of rats carrying an intrahepatic colon carcinoma,” Cancer Immunology, Immunotherapy, vol. 50, no. 9, pp. 491–501, 2001. View at Publisher · View at Google Scholar
  21. B Zhang, X T Ma, G G Zheng, G Li, Q Rao, and K F Wu, “Expression of IL-18 and its receptor in human leukemia cells,” Leukemia Research, vol. 27, no. 9, pp. 813–822, 2003. View at Publisher · View at Google Scholar
  22. G-H Jin, S-Z Jin, Y Liu et al., “Therapeutic effect of gene-therapy in combination with local X-irradiation in a mouse malignant melanoma model,” Biochemical and Biophysical Research Communications, vol. 330, no. 3, pp. 975–981, 2005. View at Publisher · View at Google Scholar
  23. R E Jr Redlinger, R B Mailliard, M T Lotze, and E M Barksdale Jr, “Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo,” Journal of Pediatric Surgery, vol. 38, no. 3, pp. 301–307, 2003. View at Publisher · View at Google Scholar
  24. H Tsutsui, K Matsui, N Kawada et al., “IL-18 accounts for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice,” Journal of Immunology, vol. 159, pp. 3961–3967, 1997. View at Google Scholar
  25. W Hashimoto, T Osaki, H Okamura et al., “Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin- induced tumor apoptosis, respectively,” Journal of Immunology, vol. 163, no. 2, pp. 583–589, 1999. View at Google Scholar
  26. M O Lee, Y H Choi, E C Shin et al., “Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): a potential mechanism for liver injury caused by hepatitis B virus (HBV) infection,” Journal of Hepatology, vol. 37, no. 3, pp. 380–386, 2002. View at Publisher · View at Google Scholar
  27. R Menon, S J Lombardi, and S J Fortunato, “IL-18, a product of choriodecidual cells, increases during premature rupture of membranes but fails to turn on the Fas-FasL-mediated apoptosis pathway,” Journal of Assisted Reproduction and Genetics, vol. 18, no. 5, pp. 276–284, 2001. View at Publisher · View at Google Scholar
  28. J Seim, P Graff, O Amellem, K S Landsverk, T Stokke, and E O Pettersen, “Hypoxia-induced irreversible S-phase arrest involves down-regulation of cyclin A,” Cell Proliferation, vol. 36, no. 6, pp. 321–332, 2003. View at Publisher · View at Google Scholar
  29. E Kerkhoff and E B Ziff, “Cyclin D2 and Ha-Ras transformed rat embryo fibroblasts exhibit a novel deregulation of cell size control and early S phase arrest in low serum,” The EMBO Journal, vol. 9, pp. 1892–1903, 1995. View at Google Scholar